Skip to main content

ABUS

Stock
Health Care
Biotechnology

Performance overview

ABUS Price
Price Chart

Forward-looking statistics

Beta
0.65
Risk
42.24%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Company info

SectorHealth Care
IndustryBiotechnology
Employees89
Market cap$603.9M

Fundamentals

Enterprise value$484.7M
Revenue$6.4M
Revenue per employee
Profit margin0.00%
Debt to equity7.07

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.41
Dividend per share
Revenue per share$0.03
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$4M
Put-call ratio

Macro factor sensitivity

Growth+5.1
Credit+0.4
Liquidity-1.8
Inflation+5.5
Commodities+2.6
Interest Rates-1.3

Valuation

Dividend yield0.00%
PEG Ratio-9.53
Price to sales96.92
P/E Ratio-9.53
Enterprise Value to Revenue75.70
Price to book7.85

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day
Ex. dividend day

News

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.

Zacks Investment Research (May 14, 2025)
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B

JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ: ABUS) after data presentation at the European Association for the Study of the Liver International Liver Congress. The analysts said that.

Benzinga (June 28, 2022)
Moderna drops, Arbutus pops after patent ruling means vaccine maker could owe royalties on billions in COVID shot revenue

The patents subject to the court's ruling cover a lipid formulation for nucleic acid delivery, which is essential for Moderna's COVID-19 vaccines.

Business Insider (December 1, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free